Capital Partners – Talk Bio

Pliant and Acelyrin Adopt Poison Pill Defenses Against Potential Concentra Buyout

1 month ago talkbio0Tagged Acelyrin, Capital Partners, Concentra Biosciences, Contraceptives, Oral, Pliant, Poisons, Tang

Poison pill, Concentra Biosciences, Tang Capital Partners, Acelyrin, Pliant Therapeutics, hostile takeover defense

Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Private Equity Deal

6 months ago talkbio0Tagged Avid, Biological Factors, Bioservices, Capital Partners, CDMO, GHO, Private Equity

Avid Bioservices, GHO Capital Partners, Ampersand Capital Partners, biologics CDMO, private equity acquisition, $1.1 billion deal

Mallinckrodt to Sell Therakos Business Unit to CVC Capital for $925 Million

9 months ago talkbio0Tagged Capital Partners, central venous catheter (CVC) sets, Extracorporeal, Healthcare services, Immunotherapy, Lymphoma, T-Cell, Cutaneous, mallinckrodt, medical technology, Photopheresis, RNASE3 gene, Therakos

Mallinckrodt, Therakos, CVC Capital Partners, photopheresis, extracorporeal photopheresis, ECP, cutaneous T-cell lymphoma, CTCL, immunotherapy, pharmaceuticals, medical technology, healthcare services